Home » Newsletters » BioWorld Science

BioWorld Science

July 14, 2000

View Archived Issues

Marked and rapid drops in food intake and body weight seen with novel FAS inhibitor

Topical doxepin/capsaicin effective in neuropathic pain relief

Phase I Endostatin trial to enroll 12 additional patients

Antisoma resumes enrollment in SMART phase III trial

AmB-cochleates compared to other AmB formulations in mouse systemic candidiasis

Two new cardiovascular genes selected in Transgene/HGS collaboration

Serono licenses TNF antibody patents to Knoll and Centocor

Invicorp upgraded to partial clinical hold in U.S.; full approval received in New Zealand

AstraZeneca receives E.U. approval for Nexium

Abgenix and Lexicon Genetics establish antibody drug discovery alliance

Interim results of phase III Synsorb Pk trial disappointing

Joint venture for OvaRex initiated by AltaRex in Middle East

Late-stage development products dropped from Taisho pipeline

Pagoclone as an effective treatment for panic disorder

Profile of new cognition enhancer AC-3933 presented this week at CINP

Differential effects on cognition reported for single and multiple doses of E-5842

CINP news: sleep and endocrine effects of sarizotan, a potential new atypical antipsychotic

Next-generation AD therapeutics based on Abeta modulation

Enhanced activity of HIV entry inhibitor combinations reported by Progenics at Durban meeting

Aventis discovers utility of riluzole in hearing disorders

Nonsteroidal antiinflammatory agents with reduced metabolic effects presented by Schering

Roche presents new cephalosporins effective against sensitive and resistant bacterial strains

Integrin-inhibitory compounds designed by Celltech for inflammatory and immune conditions

TGF-beta1 inhibitor peptides and their use in hepatic diseases described by Spanish group

New chemotherapeutic and photochemotherapeutic agents from Buckman

Agents useful for transferring nucleic acids into cells patented by Aventis

Methods of treating or preventing arthritic conditions with MEK inhibitors

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...